Look back at pharma news in week to September 28

30 September 2018

Last week’s top news stories including some positive and exciting new research data, including Amarin's trial of Vascepa in cardiovascular outcomes that beat expectations am sent the firm’s shares rocketing. There were also strong results for Roche’s immuno-oncology drug Tecentriq in a small population of small cell lung cancer patients, and Takeda’s successful trial of Alunbrig in lung cancer. On the regulatory front, AstraZeneca’s lung cancer drug Imfinzi gained European approval, adding to competition in the sector, while Verastem gained US Food and Drug Administration clearance for its blood cancer drug Copiktra, but with a Black Box warning.

Amarin lands the catch of a lifetime

Top-line result from Amarin’s REDUCE-IT trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product, comments Amy Brown on Vantage, the editorial arm of the Evaluate group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK